We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Reference Material Aims to Improve Comparability of Angiotensin II Testing

By LabMedica International staff writers
Posted on 15 Sep 2026

Comparability of biomarker measurements across laboratories remains a persistent hurdle for clinical decision-making and method development. More...

Angiotensin II, a peptide hormone central to blood pressure and fluid-electrolyte regulation and used as a vascular disease biomarker, lacks easily accessible, consistent benchmarks. The limited supply of existing international reference materials further complicates traceability and validation. To address this gap, a new study describes the development and characterization of an additional reference material intended to strengthen comparability in angiotensin II testing.

Researchers developed and characterized a candidate reference material for angiotensin II (Ang II) to provide an additional measurement benchmark. The material is intended to serve as a common standard that laboratories can use to validate analytical methods, evaluate measurement performance, and compare results across platforms. The approach addresses practical barriers to method harmonization when current international materials are difficult to access or limited in supply.

Purity assignment relied on two independent metrological strategies—isotope dilution mass spectrometry (ID‑MS) and the mass balance method—that are based on different measurement principles. Despite their distinct principles, the two approaches yielded closely consistent results, increasing confidence in the assigned value. The material demonstrated excellent bottle-to-bottle homogeneity, and the relative expanded uncertainty of the assigned value was 1.8% (k=2).

For practical deployment, stability testing showed the material remained stable for at least 12 months at −20°C. Under simulated transportation conditions, it was stable for at least seven days at both 4°C and 25°C. Measurements were also verified against NRC ANG II-1, a certified reference material from the National Research Council Canada, and the comparison met the accepted equivalence criterion, supporting the accuracy of the assigned value.

According to the study, published in Biomedical Analysis, the new reference material can support method validation, laboratory quality control, performance evaluation, and traceable measurement of Ang II, helping make results more comparable across methods and laboratories. The authors note that characterization focused on metrological properties rather than biological activity. Its biological activity has not yet been examined, and further studies will be needed to determine whether it retains equivalent activity in vivo. Within this scope, the material provides an additional tool to strengthen standardization and traceability in Ang II testing.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.